Dataset Information

Exosomes of Human blood plasma Lc-MS/MS

ABSTRACT: Immunoglobulin diversity includes B-cell receptor, T-cell receptor, and antibody diversity. Existing studies focus more on the role of B-cell and T-cell receptor diversity in tumor immunity, while little is known about antibody diversity. This study examined and compared the blood exosomes of lung cancer patients and healthy individuals via proteomics and bioinformatics analyses. The results showed that of the 270 identified proteins, those enriched in the defense mechanism items were the most abundant. Most were antibody subtype molecules, accounting for 50.00%. Similarly, of the 40 identified exosomal DEPs, 29 were enriched in the defense mechanism items (72.50%), with a higher proportion of antibody subtypes (82.76%). Furthermore, 24 DEP antibody molecules were involved in 18 immune reaction-related signaling pathways. These results indicated that human serum exosomes contained a large number of antibody molecules, while the antibody subtypes from the lung cancer serum exosomes differed from those of the healthy controls. The variation in antibody diversity may be closely related to LA tumor immunity.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Lung Cancer

SUBMITTER: bhpsky 巴红平

LAB HEAD: Yang peng

PROVIDER: PXD054628 | Pride | 2025-05-07

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	T480_LFQ_WKB001_C1_3.raw	Raw
	T480_LFQ_WKB001_C4_6.raw	Raw
	T480_LFQ_WKB001_C7_9.raw	Raw
	T480_LFQ_WKB001_LC1_3.raw	Raw
	T480_LFQ_WKB001_LC4_6.raw	Raw

Items per page:

1 - 5 of 7

Publications

Proteomic profile of the antibody diversity in circulating extracellular vesicles of lung adenocarcinoma.

Huang Xinfu X Xiong Lijuan L Zhang Yang Y Peng Xin X Ba Hongping H Yang Peng P

Scientific reports 20241114 1

Immunoglobulin diversity encompasses B-cell receptor, T-cell receptor, and antibody diversity. Existing studies have focused more on the role of B-cell and T-cell receptor diversity in tumor immunity, while the role of antibody diversity is less understood. This study examined and compared the blood extracellular vesicles (EVs) of lung cancer patients and healthy individuals using proteomics and bioinformatics analyses. The results revealed that among the 270 identified proteins, those involved ...[more]

PMID: 39543163

Similar Datasets

Project description:Background: Docosahexaenoic acid (DHA) is a natural compound with anticancer and anti-angiogenesis activity that is currently under investigation as both a preventative agent and an adjuvant to breast cancer therapy. However, the precise mechanisms of DHA’s anticancer activities are unclear. It is understood that the intercommunication between cancer cells and their microenvironment is essential to tumor angiogenesis. Exosomes are extracellular vesicles that are important mediators of intercellular communication and play a role in promoting angiogenesis. However, very little is known about the contribution of breast cancer exosomes to tumor angiogenesis or whether exosomes can mediate DHA’s anticancer action. Results: Exosomes were collected from MCF7 and MDA-MB-231 breast cancer cells after treatment with DHA. We observed an increase in exosome secretion and exosome microRNA contents from the DHA-treated cells. The expression of 83 microRNAs in the MCF7 exosomes was altered by DHA (>2-fold). The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity. These microRNAs were also increased by DHA treatment in the exosomes from other breast cancer lines (MDA-MB-231, ZR751 and BT20), but not in exosomes from normal breast cells (MCF10A). When DHA-treated MCF7 cells were co-cultured with or their exosomes were directly applied to endothelial cell cultures, we observed an increase in the expression of these microRNAs in the endothelial cells. Furthermore, overexpression of miR-23b and miR-320b in endothelial cells decreased the expression of their pro-angiogenic target genes (PLAU, AMOTL1, NRP1 and ETS2) and significantly inhibited tube formation by endothelial cells, suggesting that the microRNAs transferred by exosomes mediate DHA’s anti-angiogenic action. These effects could be reversed by knockdown of the Rab GTPase, Rab27A, which controls exosome release. Conclusions: We conclude that DHA alters breast cancer exosome secretion and microRNA contents, which leads to the inhibition of angiogenesis. Our data demonstrate that breast cancer exosome signaling can be targeted to inhibit tumor angiogenesis and provide new insight into DHA’s anticancer action, further supporting its use in cancer therapy. Examination of small RNA populations in MCF7 cells and exosomes after DHA treatment.